Clinical trials: Dry Eye Disease (DED)
Dry Eye Syndromes
Efficacy of T2259 in DED
The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.
- Trial name
- NCT03874429
- Testing
- T2259, Vismed multi
- Where
- France
- Volunteers
- 101 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease (DED), Cataract Surgery
POST CATARACT SURGERY DRY EYE DISEASE
Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms…
- Trial name
- NCT07715266
- Testing
- NOX-01
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- NOXELIS
Meibomian Gland Dysfunction, Dry Eye Disease
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
- Trial name
- NCT06064071
- Testing
- Nordlys SWT IPL, Meibomian Gland Expression (MGX)
- Where
- 3 sites in United States, Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Dry Eye Disease
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
- Trial name
- NCT03292809
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 9 sites in United States
- Volunteers
- 328 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5%…
- Trial name
- NCT06329791
- Testing
- AZR-MD-001, Vehicle
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- Azura Ophthalmics
Dry Eye
Evaluation of the Performance of MAF-1217 on Cataract Surgery
MAF-1217 is meant as the medical device which is to be effective in most forms of DED; therefore, it is expected that study patients benefit from study participation, and can reduce the signs and symptoms of surgery induced DED…
- Trial name
- NCT03833908
- Testing
- MAF-1217
- Where
- 2 sites in Italy
- Volunteers
- 46 people
- Sponsor
- VISUfarma SpA
Dry Eye
Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
SDP-4-CS201, is a Phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the ocular and systemic safety and efficacy of SDP-4 ophthalmic solution in subjects…
- Trial name
- SDP-4-CS201 (NCT03889886)
- Testing
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%)
- Where
- 26 sites in United States
- Volunteers
- 305 people
- Sponsor
- Silk Technologies, Ltd.
Dry Eye Disease (DED)
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
- Trial name
- NCT04393441
- Testing
- 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allergan
Dry Eye Disease
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
The primary objective is to evaluate the tolerability and efficacy of CWT-f-002 lubricant eye drops in the treatment of the signs and symptoms of dry eye disease.
- Trial name
- NCT05660681
- Testing
- glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Calm Water Therapeutics LLC
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study of EBI-005 in Dry Eye Disease (DED)
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye…
- Trial name
- EBI-005 (NCT02405039)
- Testing
- EBI-005
- Where
- 12 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eleven Biotherapeutics
Dry Eye Disease (DED)
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.
- Trial name
- NCT06879782
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Dry Eye Disease
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT06323395
- Testing
- Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops
- Where
- 2 sites in Serbia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease
Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease
A prospective, non- interventional, observational, non-comparative, longitudinal cohort study design will be used to address the objectives of this study using data collected through a healthcare.
- Trial name
- NCT05857748
- Testing
- lifitegrast
- Sponsor
- Novartis Pharmaceuticals
Keratitis, Autoimmunity
A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases.
Immune-related ocular surface diseases are a kind of non-infectious eye disease pedigree, which is mediated by abnormal immune system function and characterized by ocular surface tissue damage.
- Conditions
- Keratitis, Autoimmunity, Dry Eye Disease (DED)
- Trial name
- NCT07902687
- Testing
- MSCohi-O lens
- Volunteers
- 20 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Dry Eye Disease (DED)
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry…
- Trial name
- NCT07068958
- Testing
- 0.25% RCI001 Ophthalmic Solution
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Dry Eye
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
- Trial name
- NCT06565650
- Testing
- Miebo, Saline
- Where
- 12 sites in United States
- Volunteers
- 216 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes, Eye Diseases
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
- Trial name
- NCT05814757
- Testing
- OTX-DED, Controlled Insertion, Collagen Punctal Plug
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ocular Therapeutix, Inc.
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Dry Eye Disease (DED)
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland…
- Trial name
- NCT04140227
- Testing
- NOV03
- Where
- 28 sites in United States
- Volunteers
- 256 people
- Sponsor
- Bausch & Lomb Incorporated